Fundamentos: A gest&atilde;o otimizada da terapia antiplaquet&aacute;ria perioperat&oacute;ria para pacientes com stents coron&aacute;rios n&atilde;o foi completamente esclarecida. Os dados atualmente dispon&iacute;veis sobre a seguran&ccedil;a e efic&aacute;cia de diferentes regimes antiplaquet&aacute;rios entre os pacientes submetidos &agrave; cirurgia com stent t&ecirc;m resultados inconsistentes. Com isso, um consenso foi elaborado por v&aacute;rias sociedades nacionais na It&aacute;lia, incluindo a<a href="https://solaci.org/en/2015/06/24/antiagregacao-plaquetaria-em-pacientes-no-peri-operatorio-de-cirurgias-cardiacas-e-nao-cardiacas-2/" title="Read more" >...</a>

Fundamentos e objetivo: Pacientes com diabetes mellitus continuam a ser de alto risco para reestenose e eventos cardiovasculares adversos apesar do uso de stents farmacol&oacute;gicos (DES). Os DES de segunda gera&ccedil;&atilde;o oferecem resultados superiores em seguran&ccedil;a e efic&aacute;cia quando comparados aos DES de primeira gera&ccedil;&atilde;o. O stent eluidor de everolimus &eacute; o DES com evid&ecirc;ncias<a href="https://solaci.org/en/2015/06/24/reservoir-trial-demonstra-nao-inferioridade-de-um-stent-farmacologico-sem-polimero-em-pacientes-diabeticos-2/" title="Read more" >...</a>

A bioabsorbable platform implant in the context of ST segment elevation acute myocardial infarction is feasible although the subsequent cicatrization of the artery is not documented. The objective of this work was to evaluate optical coherence tomography (OCT) in patients who received everolimus-releasing bioabsorbable platform in the context of primary angioplasty. A total of 39<a href="https://solaci.org/en/2015/06/24/bvs-stemi-first-oct-study-bioabsorbable-platform-in-acute-myocardial-infarction/" title="Read more" >...</a>

Objetivos: O novo stent Biolimus-A9 (BA9) livre de pol&iacute;mero BioFreedom (Biossensores Europe SA, Morges, Sui&ccedil;a) foi estudado usando follow-ups (FU) sequenciais longitudinais por tomografia de coer&ecirc;ncia &oacute;ptica (OCT). M&eacute;todos e resultados: O endpoint prim&aacute;rio do estudo foi o percentual de cobertura das hastes do stent aos 30 dias e 9 meses por OCT. Foram realizados<a href="https://solaci.org/en/2015/06/24/estudo-ego-biofreedom-follow-up-sequencial-longitudinal-por-oct-de-stent-sem-polimero-liberador-de-biolimus-a9-2/" title="Read more" >...</a>

Fundamentos: Ainda h&aacute; controv&eacute;rsias em rela&ccedil;&atilde;o &agrave; superioridade dos pol&iacute;meros absorv&iacute;veis em rela&ccedil;&atilde;o aos pol&iacute;meros dur&aacute;veis, e v&aacute;rios estudos com a compara&ccedil;&atilde;o entre esses dois modelos vem sendo realizados. Objetivos: Comparar os desfechos cl&iacute;nicos em 3 anos entre o stent eluidor de sirulimus com pol&iacute;mero absorv&iacute;vel MiStent&reg; (APSES) com um stent eluidor de everolimus com<a href="https://solaci.org/en/2015/06/24/stent-eluidor-de-sirolimus-com-polimero-absorvivel-apresenta-superioridade-em-relacao-a-stent-eluidor-de-everolimus-com-polimero-duravel-2/" title="Read more" >...</a>

This observational registry compared the results of myocardial revascularization with angioplasty performed using everolimus-eluting stents in patients with multivessel. The primary endpoint of the study was mortality from any cause. Side end points were infarction, stroke, and revascularization. Propensity score was used to compare populations. Between 34819 patients were eligible 9223 patients in each group<a href="https://solaci.org/en/2015/06/24/best-similar-mortality-among-angioplasty-with-des-everolimus-and-surgery/" title="Read more" >...</a>

The aim of this study was to compare the usefulness of primary angioplasty only to culprit vessel versus complete revascularization guided by fractional flow reserve (FFR) in patients admitted pursuing an acute myocardial infarction with ST-segment elevation and have multiple injuries vessels. After a successful primary angioplasty to culprit artery, patients were randomized 1:1 to<a href="https://solaci.org/en/2015/06/24/danami3-primary-angioplasty-to-culprit-vessel-versus-multivessel-guided-by-ffr/" title="Read more" >...</a>

Article This multicenter randomized control study with placebo was designed to determine the risks and benefits of double antiaggregation for longer than 12 months post DES stenting. 9961 patients were randomized to continue on placebo or thienopyridine after 12 months. Thienopyridine reduces the incidence of in-stent thrombosis (0.4% vs 1.4%; p&lt;0,001) and cardiovascular events (4.3%<a href="https://solaci.org/en/2015/06/24/dapt-trial-double-antiaggregation-remains-controversial/" title="Read more" >...</a>

Current guidelines suggest treating only the culprit artery of myocardial infarction with ST-segment elevation. This prospective and randomized work included 296 patients in 7 centers suffering ST-segment elevation acute myocardial infarction referred for primary angioplasty randomized to treat only the culprit artery (n = 146) versus complete revascularization (n = 150).&nbsp; In the culprit artery<a href="https://solaci.org/en/2015/06/24/culprit-complete-revascularization-versus-culprit-artery-of-infarct-only/" title="Read more" >...</a>